News and Views

Nature Medicine 13, 1018 - 1019 (2007)
doi:10.1038/nm0907-1018

Schizophrenia drug says goodbye to dopamine

Daniel R Weinberger1

  1. Daniel R. Weinberger is at the Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA. e-mail: daniel.weinberger@mail.nih.gov

A drug that activates glutamate receptors offers promise for a new class of anti-psychotic therapeutics and sheds light on the pathophysiology of this devastating disease (pages 1102–1107).

Top


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

An emerging pathophysiology

Nature News and Views (13 Feb 1997)

Neuroscience A complex in psychosis

Nature News and Views (06 Mar 2008)

RESEARCH

Stimulation of α2-Adrenoceptors Suppresses Excitatory Synaptic Transmission in the Medial Prefrontal Cortex of Rat

Neuropsychopharmacology Original Article

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Nature Medicine Letter (01 Sep 2007)

See all 45 matches for Research

Extra navigation

Subscribe to Nature Medicine

Subscribe

See also

Search PubMed for

Open Innovation Challenges

  • Single-cell Analysis Platform

    • Deadline: Dec 02 2009
    • Reward: $5,000 USD

    This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...

  • Optimizing Sub-cellular Localization Tags

    • Deadline: Jan 31 2010
    • Reward: $20,000 USD

    The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....

naturejobs

More science jobs
Post a job for free

ADVERTISEMENT